-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
The National Institute of Health and Clinical Optimization (NICE) recently released the final draft guidance, recommending that Bristol-Myers Squibb tumor immunotherapy Opdivo (nivolumab) be included in the British National Health Service (NHS) as a routine use to treat metastatic and recurrent head and neck Cancer patients
.
In January of this year, NICE issued a draft guidance that rejected Opdivo for the treatment of head and neck squamous cell carcinoma (SCCNH) that recurred or metastasized after receiving platinum-containing chemotherapy
.
At that time, NICE stated that evidence collected in Opdivo’s clinical trials and through the NICE Cancer Drug Fund (CDF) showed that SCCHN patients treated with Opdivo survived compared with patients treated with one of the three therapies in the control group.
However, NICE added that these results are uncertain
.
Because one of the contrast therapies-docetaxel-is used as the standard treatment for these patients in the NHS
However, new evidence collected from the CDF suggests that patients treated with Opdivo may survive 9 months longer than patients treated with other therapies
.
NICE added that despite this, it is not clear how effective Opdivo compares to the "most relevant control drug" docetaxel
In the end, NICE concluded that Opdivo meets the criteria that it can be considered as a life-prolonging treatment at the end of life.
In terms of cost-benefit evaluation, Opdivo is now considered to be within the acceptable criteria for using NHS resources
.
Head and neck cancer refers to a group of cancers that start in the head and neck.
It usually occurs in the squamous cells on the moist mucosal surface of this area of the body, such as the mouth, nose, and throat
.
Head and neck cancer is the sixth most common cancer in the world, with an estimated 930,000 new cases and 467,000 deaths each year
Opdivo is an anti-PD-1 monoclonal antibody drug approved in the European Union in May 2017.
It has become the first drug in the market for the treatment of SCCHN in more than a decade, and it is also the first immunity approved for the treatment of platinum-refractory SCCHN in the market.
Oncology drugs
.
The approval is based on data from the pivotal Phase 3 CHECKMATE-141 study
.
The study was carried out in 361 adult patients with relapsed or metastatic platinum-refractory SCCHN, combining Opdivo with a treatment plan selected by the investigator (one of three: methotrexate, docetaxel, or cetuximab).
Reference source: NICE backs Opdivo for head and neck cancer-PharmaTimes
(The original text has been deleted)
